Antigen Binding Domain definition

Antigen Binding Domain means an extracellular target binding domain derived from a single-chain variable fragment (scFv) of a monoclonal antibody (or from other sources, such as Fab libraries or invariant human ligands).
Sample 1Sample 2Sample 3
Antigen Binding Domain means a protein fragment (such as an scFv) constructed from one (1) or more CDRs of an antibody, which protein fragment is Directed to a specific tumor-associated antigen.
Sample 1Sample 2

Examples of Antigen Binding Domain in a sentence

  • Pursuant to the Ono Letter Agreement, Ono delivered to us proprietary antigen binding domains targeting an antigen expressed on certain solid tumors and nominated such antigen binding domains as the Ono Antigen Binding Domain for incorporation into Candidate 2.

  • In the case ONO has not delivered to FATE the ONO Antigen Binding Domain [***] (or the end of any extended period that is mutually agreed by the Parties) and thereafter [***] ONO shall pay to FATE [***] Dollars ($[***])[***], in which ONO will be granted the license for [***] or (b) [***] Dollars ([***]) [***] in which ONO will be granted the license for [***].

  • ONO shall manufacture, handle, store and ship all such ONO Antigen Binding Domain in compliance with all Laws, with all Regulatory Filings, and with its applicable internal specifications and quality control procedures during the Research Term.

  • This exclusion is not consistent with the subjective experiences of suspects, who often perceive arrests as force, or with the ordinary use of language, in which a private individual who handcuffed and restrained another person would likely be seen as a violent criminal.128 Nor is a resistance requirement as a component of police force entirely consistent with every aspect of constitutional doctrine.

  • Sadly though, we don’t see Steven Spielberg clamouring for the film rights to Jaws: Vital Source Of Proteins That Mimic The Shape and Stability of a Crucial Antigen Binding Domain.

  • The AARM includes management reviews according to the objectives as described in Section II of Directive 8.14.

  • The JSC shall also serve as a forum for information exchange with respect to (i) ONO's research and development activities with respect to the ONO Antigen Binding Domain and/or (ii) ONO's and FATE's research and development activities with respect to the Alternative Antigen Binding Domain, provided that subject to [***], such activities regarding above (i) shall not be subject to the oversight or decision making of the JSC.

  • As of the Amendment 01 Effective Date, ONO has designated [***] as [***] and certain ONO Antigen Binding Domain(s) directed to [***] as ONO Antigen Binding Domain [***] pursuant to the Letter Agreement.

  • Option-2: Electronic Fund Transfer (EFT: NEFT/RTGS) If the bidder selects payment mode as EFT (NEFT/RTGS), “Paying Slip for EFT (NEFT/RTGS)” will be generated by the system for the complete amount.

  • If ONO does not provide [***] within [***] of the Amendment 01 Effective Date, then ONO shall be deemed to have terminated the Agreement with respect to [***] in its entirety (the “[***] Termination”).] 2.4 All references in the Agreement to ONO Antigen Binding Domain shall read ONO Antigen Binding Domain [***] (and, as such, applicable solely to [***]).

Related to Antigen Binding Domain

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Receptor means enclosed spaces, conduits, protected groundwater sources, drinking and non-drinking water wells, surface water bodies, and public water systems which when impacted by chemicals of concern may result in exposure to humans and aquatic life, explosive conditions or other adverse effects on health, safety and the environment as specified in these rules.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Proprietary school means a school that uses a certain plan or method to teach a trade, occupation, or vocation for a consideration, reward, or promise of any kind. Proprietary school includes, but is not limited to, a private business, trade, or home study school. Proprietary school does not include any of the following:

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Genetic material means any material of plant, animal, microbial or other origin containing functional units of heredity.

  • Preceptor means an individual who provides, directs, or verifies training and experience required for an individual to become an authorized user, an authorized medical physicist, an authorized nuclear pharmacist, or a radiation safety officer.

  • Victim or target of Nazi persecution means any individual persecuted or targeted for persecution by

  • Valid write-in candidate means a candidate who has qualified as a write-in

  • Therapeutic school means a residential group living facility:

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Proprietary Technology means the technical innovations that are unique and

  • Reference biological product means the single biological product licensed pursuant to 42 U.S.C.

  • Program Technology means Program Know-How and Program Patents.

  • Cell Line means the cell line, particulars of which are set out in Schedule 1.

  • Opioid antagonist means a drug that binds to opioid

  • Joint Know-How has the meaning set forth in Section 8.1.2.

  • Diagnostic mammography means a method of screening that

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Image receptor means any device, such as a fluorescent screen or radiographic film, which transforms incident X-ray photons either into a visible image or into another form which can be made into a visible image by further transformations.

  • Corrosion inhibitor means a substance capable of reducing the corrosivity of water toward metal plumbing materials, especially lead and copper, by forming a protective film on the interior surface of those materials.

  • High-technology activity means that term as defined in section 3 of the Michigan economic growth authority act, 1995 PA 24, MCL 207.803.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Licensed Know-How means all Know-How that (a) is Controlled by Pfizer or any of its Affiliates as of the effective date of the Pfizer-MPP Agreement, (b) directly relates to the use of the Compound, Product or Licensed Product in the Field, and (c) is not in the public domain or otherwise generally known. For the avoidance of doubt, (i) Licensed Know-How shall not include any Know-How to the extent solely and directly related to any other Pfizer compound or to the extent related to the use of the Compound, Product or Licensed Product outside the Field and (ii) Licensed Know-How includes only that Know-How, designated by Pfizer in its sole discretion, necessary for the manufacture, registration and commercialization of the Compound and/or Licensed Product for use in the Field. For the avoidance of doubt, Licensed Know-How excludes any Know-How related to ritonavir that has been (either as of the Effective Date or at any time during the term of this Agreement) in-licensed by Pfizer from any Third Party.